Hexarelin Frequently Asked Questions

Hexarelin (Examorelin) is a synthetic hexapeptide growth hormone secretagogue structurally related to GHRP-6 but with greater potency. It stimulates robust growth hormone release from the pituitary gland and has demonstrated cardioprotective properties in preclinical studies. Peptides Pharma Hexarelin is formulated at >99% purity in a lyophilized vial.

Hexarelin activates the growth hormone secretagogue receptor (GHS-R1a) and has also been shown to bind to CD36 receptors in cardiac tissue, which is linked to its cardioprotective effects. It produces a dose-dependent increase in GH release, though research indicates desensitisation may occur with prolonged continuous use. These findings are from published preclinical and clinical studies.

Hexarelin is studied in research related to growth hormone secretion, cardiac function and protection, body composition, bone density, and neuroendocrine regulation. Its dual activity on GHS-R1a and CD36 receptors makes it uniquely relevant to both endocrine and cardiovascular research.

Peptides Pharma Hexarelin is manufactured to >99% purity in GMP-certified, ISO 7 cleanroom facilities. Each batch undergoes rigorous third-party HPLC and mass spectrometry testing. Certificates of Analysis are available for every production batch.

Lyophilized Hexarelin should be stored at -20°C for long-term storage or 2-8°C for shorter periods. Keep away from direct light and moisture. Once reconstituted, store at 2-8°C and use within 28 days.

Add bacteriostatic water slowly along the inner wall of the vial to prevent damage to the peptide structure. Gently swirl until fully dissolved — do not shake vigorously. Select the reconstitution volume based on your target concentration for the research protocol.

Reconstituted Hexarelin stored at 2-8°C with bacteriostatic water typically maintains stability for up to 28 days. Maintain sterile technique when withdrawing doses to prevent microbial contamination of the remaining solution.

Yes. Peptides Pharma Hexarelin is supplied exclusively for laboratory and research use. It is not approved as a medicine and is not intended for human therapeutic application. Researchers should adhere to all relevant institutional and regulatory guidelines.

Published research protocols have used varying Hexarelin doses depending on the study model and endpoint. Researchers should refer to peer-reviewed literature specific to their area of investigation for appropriate dosing parameters. Note that desensitisation has been reported with prolonged continuous administration in some studies.

Hexarelin may be studied alongside GHRH analogues such as CJC-1295 for synergistic GH release through complementary receptor pathways. However, researchers should account for Hexarelin's broader hormonal effects (including potential cortisol and prolactin elevation) when designing combination protocols. Protocol design should be guided by published literature.